Chiltern Develops Functional Service Model Relationships in Western Europe
London, UK-September 3, 2009
Chiltern International Limited, a global clinical research organization (CRO) has been selected as the sole provider of clinical research staff for the monitoring aspect of all clinical research projects for Western Europe for a top pharmaceutical company.
All CRAs will be seconded via Chiltern’s European Resourcing Solutions team and fully allocated to the company under a Functional Service or FSP model. The Chiltern CRAs will work directly with the client Project Managers.
Another leading pharmaceutical company also selected Chiltern as the sole provider of an FSP relationship within their pharmacovigilance team. FSP relationships are gaining popularity in the industry due to the flexibility in resource allocations and the cost savings they can offer to clients.
“These are great achievements for Chiltern,” commented Linda Christmas, Chiltern Executive Vice President, Resourcing Solutions, “and helps us meet our target to develop strategically aligned relationships with our clients. We are delighted that we have been able to partner with two more leading pharmaceutical companies in two different core functions.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
